Ipreziv

RSS

azilsartan medoxomil

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Ipreziv has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 19/12/2014

Authorisation details

Product details
Name
Ipreziv
Agency product number
EMEA/H/C/002517
Active substance
Azilsartan medoxomil
International non-proprietary name (INN) or common name
azilsartan medoxomil
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09CA09
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Takeda Pharma A/S
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
07/12/2011
Contact address
Dybendal Alle 10
2630 Taastruup
United Kingdom

Product information

27/10/2014 Ipreziv - EMEA/H/C/002517 - A31/0006

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Agents acting on the renin angiotensin system

Therapeutic indication

Ipreziv is indicated for the treatment of essential hypertension in adults.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating